- AASTOCKS
阿斯利康首次承認新冠疫苗可引致血栓 面對逾億英鎊索償
英國藥廠阿斯利康(AstraZeneca)及牛津大學合作研發的新冠疫苗，懷疑引致接種者出現血栓，英國多家傳媒報道，阿斯利康在法庭文件中首次承認，其新冠疫苗可能導致部份接種者出現罕見的副作用「血栓伴血小板減少綜合症(Thrombocytopenia Syndrome)。 阿斯利康日前在一宗法院個案中承認疫苗有副作用，受害者斯科特(Jamie Scott)現年44歲，在2021年4月接種疫苗後身體不適，送醫後確診腦血栓，腦部永久性受損而無法工作，獲英國政府透過疫苗賠償機制賠償12萬英鎊，現時出現聽講讀寫困難，雙眼部分失明等後遺症。 據報英國高等法院已收到51宗案件，受害者及其家人要求賠償超過1億英鎊。(cy/k)~ 阿思達克財經新聞 網址: www.aastocks.com
- Insider Monkey
AstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript
AstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript April 25, 2024 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.03 EPS, expectations were $1.22. AstraZeneca PLC isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning to those joining […]
- Benzinga
AstraZeneca Admits Its COVID-19 Vaccine May Cause Blood Clotting Side Effect In Very Rare Case, But Causal Mechanism Unknown
European pharma giant AstraZeneca Plc’s (NASDAQ:AZN) Covid vaccine, developed with the University of Oxford, is facing a class action lawsuit alleging its vaccine caused death and serious injury in numerous cases. Lawyers representing the plaintiffs argue that the vaccine resulted in side effects for a small number of families, including brain injuries and fatalities. AstraZeneca, while contesting the claims, has acknowledged in court documents that its vaccine can, in rare instances, cause Thro
